Monoclonal Therapeutics and Companion Diagnostic Products

Published - Jan 2008| Analyst - Kim Lawson| Code - BIO016G
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

This Report:

  • The global market for monoclonal therapeutic and diagnostic antibodies increased from $26 billion in 2006 to an estimated $31 billion by the end of 2007. It should reach $56 billion by 2012, a compound annual growth rate (CAGR) of 13%.
  • In 2007, the U.S. Food and Drug Administration approved 21 therapeutic monoclonal antibodies for therapeutic use under a drug approval review.
  • Monoclonal antibodies are a significant part of effective medical treatment and of financial deals within the biotechnology and pharmaceutical sectors of the economy.

INTRODUCTION

BCC's goal in conducting this study was to determine the current status of the global therapeutic and diagnostic markets for monoclonal antibodies and their growth potential over a 5 year period from 2007 to 2012. We were particularly interested in the position of the antibody market in the immediate future compared to how it has performed in the recent past as well as how the market compares to that of small molecule pharmaceuticals.

Our key objective was to present a comprehensive analysis of the current monoclonal antibody market and its future direction.

SCOPE OF STUDY

This report contains:

 

  • Descriptions of various types of monoclonal therapeutic and diagnostic antibodies in terms of their history in medicine, their types and technology categories
  • The current market status for monoclonal therapeutic and diagnostic antibodies, trends and forecasts for growth over the next 5 years
  • Technological issues including the latest trends and a thorough patent analysis
  • Analysis of the monoclonal therapeutic and diagnostic antibodies industry on a worldwide basis, both from a market and application perspective
  • Discussion of government support in major regions of the world.

 

METHODOLOGY

BCC presents an analysis of the types of technologies, applications, and therapeutic areas representing financial value in the area of monoclonal antibodies in medicine. Estimated values are based on actual aggregate sales for the years discussed. Information, in general, is compiled through a combination of primary and secondary research, including annual reports and interviews with company officials.

INFORMATION SOURCES

BCC presents an analysis of the types of technologies, applications, and therapeutic areas representing financial value in the area of monoclonal antibodies in medicine. Estimated values are based on actual aggregate sales for the years discussed. Information, in general, is compiled through a combination of primary and secondary research, including annual reports and interviews with company officials.

ABOUT THE AUTHOR

Kim Johnson is a graduate of Mount Holyoke College with a degree in English Literature. She acquired experience as a health care journalist, including working for John Wiley & Sons for years as a print reporter, before serving as a research analyst in a small market research firm that focused on pharmaceuticals and biotechnology in the Research Triangle Park area of North Carolina. Before joining that firm, Kim published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.

 

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Aug-2005| Analyst - Lynn Gray| Code - BIO016F

Report Highlights

  • The worldwide market for therapeutic and diagnostic antibodies is estimated at $15 billion in 2005 and will rise at an average annual growth rate (AAGR) of 11.5% to nearly 26 billion in 2010.
  • Therapeutic antibodies dominate the market and are projected to have an AAGR of 11.4%, reaching $25.7 billion in 2010.
  • The therapeutic monoclonal antibody segment will rise at an AAGR of 12.4% while the therapeutic polyclonal market, driven more by volume and demand than innovation, is projected to see an AAGR of only 4%.
  • The diagnostic imaging market, though small, will experience an average annual growth near 17%, reaching $147 million in 2010.
Published - Oct-2002| Analyst - Lynn Gray| Code - BIO016E

Report Highlights

  • As of May 2002, there were 11 therapeutic monoclonal antibody products on the U.S. market. Worldwide, there were an estimated 470 monoclonal antibody products in development by more than 200 companies for the treatment of virtually every debilitating disease. Approximately 70 of these monoclonal antibody products were in clinical trials. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), monoclonal antibody products represented approximately 20% of all products in development and 33% of all biotech products in development by its members.
  • The therapeutic monoclonal antibody market is projected to have an average annual growth rate (AAGR) of approximately 25% throughout the forecast period. The therapeutic polyclonal antibody market, which is driven more by volume and demand than innovation, is projected to see an AAGR of just less than 11%. The diagnostic imaging market, though small, will see average annual growth exceeding 28% throughout the forecast period.

Published - Feb-2000| Analyst - Lynn Gray| Code - BIO016D

Report Highlights

  • Antibody-based drugs, in particular monoclonal antibody-based products, are on the brink of significant commercial growth. New developments are spurred in part by advances in technology that have now surmounted previous technical barriers to commercialization.
  • The information and analyses presented in this report on antibody-based drugs is an important asset in decision-making for managers involved in development, marketing, market research, product development, mergers and acquisitions, licensing, management, investment banking and deal creation, and to consultants to the pharmaceutical and biotechnology industry.
  • The study provides a comprehensive analysis of the current markets for antibody drugs and, in particular, the market potential of promising drugs and technologies under development.

CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report